

Supplemental online content for:

Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I–III Pancreatic Adenocarcinoma

Nina N. Sanford, MD; Todd A. Aguilera, MD, PhD; Michael R. Folkert, MD, PhD; Chul Ahn, PhD; Brandon A. Mahal, MD; Herbert Zeh, MD; Muhammad S. Beg, MD; John Mansour, MD; and David J. Sher, MD

J Natl Compr Canc Netw 2019;17(11):1292–1300

eTable 1: Multivariable aORs of Receiving Chemotherapy at Academic Centers

eTable 1. Multivariable aORs of Receiving Chemotherapy at Academic Centers

Characteristic	Any Chemotherapy (N=10,586)			Multiagent Chemotherapy (N=6,160)		
	aOR (95% CI)	P Value	% (95% CI)	aOR (95% CI)	P Value	% (95% CI)
Age (per y)	0.95 (0.94–0.95)	<.001	N/A	0.97 (0.96–0.98)	<.001	N/A
Race						
White	Ref		61.3 (60.4–62.3)	Ref		30.2 (28.3–32.1)
Black	1.03 (0.90–1.18)	.64	61.8 (59.1–64.5)	0.76 (0.57–0.99)	.046	24.8 (20.2–29.4)
Asian	1.20 (0.91–1.57)	.19	64.4 (59.0–69.8)	1.19 (0.77–1.85)	.43	34.0 (24.8–43.3)
Other	0.69 (0.46–1.06)	.09	53.3 (44.1–62.6)	0.80 (0.35–1.83)	.60	26.0 (10.8–41.2)
Sex						
Male	Ref		61.5 (60.2–62.7)	Ref		32.1 (29.7–34.4)
Female	0.99 (0.91–1.08)	.89	61.3 (60.0–62.5)	0.77 (0.65–0.91)	.002	26.7 (24.4–29.2)
Charlson-Deyo comorbidity score						
0	Ref		61.7 (60.7–62.8)	Ref		30.9 (28.8–33.0)
1	0.99 (0.90–1.09)	.89	61.6 (60.0–63.3)	0.84 (0.69–1.02)	.08	27.4 (24.1–30.6)
2	0.90 (0.75–1.08)	.24	59.1 (55.3–62.9)	0.79 (0.53–1.17)	.24	26.3 (19.2–33.4)
3	0.63 (0.47–0.85)	.003	51.8 (45.2–58.5)	0.65 (0.31–1.33)	.23	22.7 (10.6–34.9)
Cancer stage						
I	Ref		47.6 (45.0–50.2)	Ref		20.5 (14.8–26.3)
II	2.03 (1.80–2.30)	<.001	63.4 (62.4–64.3)	1.69 (1.17–2.44)	.006	30.0 (28.3–31.8)
III	2.00 (1.52–2.62)	<.001	63.0 (57.8–68.1)	2.75 (1.42–5.35)	.003	40.7 (27.8–53.7)
Readmission within 30 d of surgery						
No	Ref		62.3 (61.4–63.2)	Ref		29.8 (28.0–31.5)
Yes	0.57 (0.49–0.67)	<.001	50.1 (46.9–53.3)	0.89 (0.63–1.26)	.52	27.5 (21.0–34.0)
Insurance type						
Private insurance/managed care	Ref		63.8 (62.1–65.4)	Ref		29.7 (27.0–32.4)
Uninsured	0.59 (0.46–0.75)	<.001	52.1 (46.7–57.4)	0.45 (0.25–0.81)	.008	16.4 (8.7–24.1)
Medicaid	0.72 (0.59–0.88)	.001	56.7 (52.3–61.0)	0.75 (0.52–1.07)	.11	24.2 (17.9–30.4)
Medicare	0.88 (0.79–0.99)	.03	61.0 (59.6–62.3)	1.08 (0.86–1.35)	.51	31.2 (28.1–34.4)
Other government	1.20 (0.77–1.86)	.43	67.4 (58.7–76.1)	1.03 (0.41–2.56)	.95	30.2 (11.8–48.6)
Income level						
≥\$46,000	Ref		67.0 (65.7–68.2)	Ref		30.1 (27.8–32.5)
\$35,000–\$45,999	0.73 (0.66–0.80)	<.001	60.0 (58.2–61.7)	0.87 (0.70–1.07)	.18	27.3 (24.0–30.6)
\$30,000–\$34,999	0.56 (0.50–0.63)	<.001	54.2 (52.0–56.4)	1.08 (0.83–1.40)	.58	31.6 (26.8–36.5)
<\$30,000	0.55 (0.48–0.62)	<.001	53.7 (51.1–56.3)	1.00 (0.75–1.33)	.99	30.1 (24.8–35.3)
Treatment era						
2004–2006	Ref		57.8 (56.0–59.6)	N/A		N/A
2007–2009	1.13 (1.01–1.27)	.04	60.7 (59.0–62.4)	N/A		N/A
2011–2012	1.26 (1.12–1.42)	<.001	63.1 (61.4–64.9)	Ref		29.0 (26.3–31.7)
2013–2015	1.32 (1.17–1.48)	<.001	63.8 (62.1–65.5)	1.05 (0.88–1.24)	.60	30.0 (27.8–32.1)

Abbreviations: aOR, adjusted odds ratio; N/A, not applicable.